Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds -- Grindedal et al. 47 (2): 99 -- Journal of Medical Genetics

Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.